Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

ABSTRACT: Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

PROVIDER: PRJNA788031 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17196900.fastq.gz	Fastqsanger.gz
	SRR17196901.fastq.gz	Fastqsanger.gz
	SRR17196902.fastq.gz	Fastqsanger.gz
	SRR17196903.fastq.gz	Fastqsanger.gz
	SRR17196904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 37

Similar Datasets

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

Project description:Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

| PRJNA788021 | ENA

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

Project description:Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

| PRJNA788030 | ENA

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-09-18 | GSE190674 | GEO

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

Project description:Using a mouse-adapted SARS-CoV-2 variant (SARS-CoV-2 MA20), newly generated in our lab, we found that endogenous type I and type III IFNs synergize to limit SARS-CoV-2 replication and to expedite virus clearance and that enhanced disease progression in aged mice depends on impaired type II IFN immunity

2022-09-19 | GSE190673 | GEO

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

Project description:Using a mouse-adapted SARS-CoV-2 variant (SARS-CoV-2 MA), we found that endogenous type I and type III IFNs synergize to limit SARS-CoV-2 replication and to expedite virus clearance and that enhanced disease progression in aged mice depends on impaired type II IFN immunity

2022-09-19 | GSE190672 | GEO

Eutherian interferons

Project description:Eutherian interferons

| PRJEB36709 | ENA

ImmGen Cytokines: Interferons

Project description:ImmGen Cytokines: Interferons

| PRJNA303161 | ENA

Tree mortality soil

Project description:Tree mortality soil Raw sequence reads

| PRJNA810253 | ENA

Human lung tissue treated with interferons

Project description:RNAseq analysis of human lung slices after treatment with different interferons. Results: Differentially expressed genes were observed after treatment with different interferons. Methods: Tumor-free human lung explants were obtained from patients undergoing lung surgery at the University Hospital Muenster on the day of surgery. Tissue blocks were individually placed in a 12-well plate in RPMI medium. Tissues were treated with different interferons. RNA was prepared from tissue homogenates.

2022-08-31 | GSE188637 | GEO

The effect of interferons on presentation of defective ribosome products as HLA peptides

Project description:The class I major histocompatibility complex (MHC) bound peptides, produced from immature proteins that are degraded rapidly are called defective ribosome products (DRiPs). Such DRiPs are possibly involved with early alerting of the immune system about impeding infections, thus bringing about faster killing of infected cells before the viruses replicate. Interferons are a major group of cytokines, produced in response to viral infection. The interferons modulate the cellular metabolism and gene expression patterns and increase the expression and cell-surface presentation of the MHC molecules, helping this way coping with the viral infection. In this study, we evaluated whether the interferons also induce rapid degradation of cellular or viral proteins and produce DRiPs MHC-bound peptides to help the alert of the immune system. Cultured human breast cancer cells were treated with interferons and the cells were transferred to growth media containing heavy stable isotope labeled amino acids (dynamic-SILAC)in several time points a few hours after the interferons’ treatment. The rates of synthesis, degradation, and production of the cellular protein and their degradation products, the MHC peptides, were followed by LC-MS/MS analyses. Detection of large numbers of MHC peptides that incorporate the heavy amino acids into them, faster than their source proteins, indicated to us that not only DRiP-peptides are rather abundant among the MHC peptidome, but that the interferons increase significantly the presentation of DRiP-peptides. Importantly, much of this DRiPome derive from multi-subunit complexes, including the proteasomes and ribosomes, while the degradation of the standard protostome give rise to the immunoproteasome, which is thought to produce peptides that enhance the immune-response; the degradation of the ribosome subunits may aid in reducing the synthesis of viral infection

2021-06-09 | PXD022633 | Pride